Bauriaud R, Séror C, Lareng M B, Lefèvre J C
Groupe Etude et Prévention des Maladies Transmissibles Sexuellement, Laboratoire Central de Microbiologie, Hôpital Purpan, Toulouse, France.
Pathol Biol (Paris). 1992 May;40(5):479-82.
The minimal metabolism-inhibiting concentrations (MMC) of 11 antibiotics were determined for 40 strains each of M. hominis and U. urealyticum using a terminal color change broth method. All strains were recovered in 1990. Resistance to tetracycline (MMC greater than 8 mg/l) was found for 12.5% of strains of M. hominis and U. urealyticum, as compared with 5% in 1985. Rokitamycin was the most active macrolide against M. hominis (MMC 90: 0.06 mg/l). U. urealyticum strains were susceptible to all the macrolides tested, with the greatest activities being seen for rokitamycin and clarithromycin (MMC 90: 0.06 mg/l and 0.12 mg/l respectively). Sparfloxacin was the most active quinolone against both species. Human clinical trials designed to evaluate these new molecules for the treatment of mycoplasmal and ureaplasmal genital infections are warranted.
采用终点颜色变化肉汤法测定了11种抗生素对40株人型支原体和解脲脲原体的最低代谢抑制浓度（MMC）。所有菌株均于1990年分离得到。人型支原体和解脲脲原体中12.5%的菌株对四环素耐药（MMC大于8mg/l），而1985年这一比例为5%。罗他霉素是对人型支原体活性最强的大环内酯类抗生素（MMC90：0.06mg/l）。解脲脲原体菌株对所有测试的大环内酯类抗生素敏感，其中罗他霉素和克拉霉素活性最强（MMC90分别为0.06mg/l和0.12mg/l）。司帕沙星是对这两种菌活性最强的喹诺酮类抗生素。有必要开展人体临床试验以评估这些新分子用于治疗支原体和脲原体性生殖器感染的效果。
